[HTML][HTML] Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
AH Kverneland, CA Chamberlain… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has
shown remarkable results in malignant melanoma (MM), while studies on the potential in …
shown remarkable results in malignant melanoma (MM), while studies on the potential in …
Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma
JE Mullinax, ML Hall, S Prabhakaran, J Weber… - Frontiers in …, 2018 - frontiersin.org
Purpose Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic
melanoma can be highly effective, but attrition due to progression before TIL administration …
melanoma can be highly effective, but attrition due to progression before TIL administration …
Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future
A Betof Warner, PG Corrie, O Hamid - Clinical Cancer Research, 2023 - AACR
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …
demonstrating durable responses in patients with advanced melanoma. Although …
Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome
Purpose: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has
consistently demonstrated clinical efficacy in metastatic melanoma. Recent widespread use …
consistently demonstrated clinical efficacy in metastatic melanoma. Recent widespread use …
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
MJ Besser, R Shapira-Frommer, O Itzhaki… - Clinical Cancer …, 2013 - AACR
Purpose: Adoptive cell transfer (ACT) using autologous tumor-infiltrating lymphocytes (TIL)
was reported to yield objective responses in about 50% of metastatic patients with …
was reported to yield objective responses in about 50% of metastatic patients with …
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy
Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes
(TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but …
(TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but …
[HTML][HTML] Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma
MW Rohaan, TH Borch, JH Van Den Berg… - New England journal …, 2022 - Mass Medical Soc
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With …
ME Dudley, CA Gross, RPT Somerville… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs)
and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma …
and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma …
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown
significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion …
significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion …
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
LG Radvanyi, C Bernatchez, M Zhang, PS Fox… - Clinical Cancer …, 2012 - AACR
Purpose: Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is
a promising treatment for metastatic melanoma unresponsive to conventional therapies. We …
a promising treatment for metastatic melanoma unresponsive to conventional therapies. We …
相关搜索
- cell therapy metastatic melanoma
- cell therapy cancer types
- checkpoint inhibition cancer types
- cell therapy checkpoint inhibition
- cell therapy lymphocytes for patients
- lymphocytes in patients adoptive transfer
- cell therapy combination of ipilimumab
- cell therapy lymphocyte subsets
- cell therapy patients with melanoma